Page last updated: 2024-09-03

muramylnac-ala-isogln-lys-tripeptide and EHS Tumor

muramylnac-ala-isogln-lys-tripeptide has been researched along with EHS Tumor in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jarowenko, DG; Pellis, NR; Sigler, SC1

Other Studies

1 other study(ies) available for muramylnac-ala-isogln-lys-tripeptide and EHS Tumor

ArticleYear
Muramyl tripeptide: an effective immunotherapy in the surgical setting for pediatric abdominal neoplasms.
    Journal of pediatric surgery, 1987, Volume: 22, Issue:6

    Topics: Abdominal Neoplasms; Acetylmuramyl-Alanyl-Isoglutamine; Animals; Female; Fibrosarcoma; Immunity, Cellular; Immunotherapy; Liposomes; Macrophage Activation; Mice; Mice, Inbred C3H; Micelles; Neoplasm Seeding; Peritoneal Neoplasms; Sarcoma, Experimental; Time Factors

1987